Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,666 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Metabolic Complications Clear all

Conditions: Infections, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulation, Diabetes and Its Complications, End of Life/Desires Only Medical Management
Interventions: Home Hospital care, Traditional Hospital care; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Quincy, Illinois • Hazard, Kentucky

Conditions: Type 2 Diabetes, Diabetic Cardiomyopathy, Heart Failure, Cardiometabolic Diseases
Interventions: Intensive Prevention Strategy; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Dallas, Texas

Conditions: Gestational Diabetes, Pregnancy Complications, Pregnancy Related, Genetic Predisposition, Risk Reduction
Interventions: Polygenic Risk Score Generation; Genetic
Lead sponsor: Prenome; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 10,000 participants
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Foster City, California

Conditions: Type 2 Diabetes Mellitus, Renal Impairment
Interventions: dutogliptin, placebo, sitagliptin; Drug
Lead sponsor: Phenomix; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 23
States / cities: Tempe, Arizona • Long Beach, California • Lynwood, California + 18 more

Conditions: Infertility, Female
Interventions: Survey & Food Diary; Other
Lead sponsor: TriHealth Inc.; Other
Eligibility: 18 Years to 45 Years · Female only
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Obesity, Pregnancy Complications, Peripartum Cardiomyopathy
Interventions: NT-proBNP; Diagnostic Test
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pre Diabetes, Polycystic Ovary Syndrome, Obesity Android
Interventions: Liraglutide Pen Injector [Saxenda], Placebo Liraglutide Pen Injector; Drug
Lead sponsor: Woman's; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Diabetic Foot Ulcers
Interventions: AMNIOEXCEL, Standard of Care, Diabetic Foot Ulcers; Other
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 8
States / cities: Phoenix, Arizona • Castro Valley, California • Stockton, California + 5 more

Conditions: Gestational Diabetes Mellitus in Pregnancy, Glucose Intolerance During Pregnancy, Non-nutritive Sweeteners Consumption in Pregnancy and/or Lactation
Interventions: NNS Restriction Intervention, Control Intervention; Behavioral
Lead sponsor: George Washington University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 324 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Renal Osteodystrophy
Interventions: doxercalciferol, Cholecalciferol; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 82 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Hyperkalemia, End Stage Renal Disease
Interventions: Patiromer Oral Powder Product; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Type2diabetes, Diabetic Kidney Disease
Interventions: Investigational Product - MIB 626, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 30 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus Type 2 in Obese
Interventions: standard of care in general clinical practice; Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 12 Years to 24 Years
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 16
States / cities: Los Angeles, California • Denver, Colorado • New Haven, Connecticut + 11 more

Conditions: Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic
Interventions: Metformin, Sulfonylurea, DPP-4 inhibitor, SGLT2 inhibitor, GLP1 receptor agonist; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 4,888 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Nashville, Tennessee

Conditions: Proliferative Diabetic Retinopathy, Diabetic Retinopathy, Diabetes
Interventions: PDS Implant filled with 100 mg/mL Ranibizumab, Ranibizumab; Device · Drug
Lead sponsor: Southeast Retina Center, Georgia; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Diabetes, Gestational, PreDiabetes, Diabetes Mellitus, Type 2
Interventions: Metformin; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Osteoporosis, Turner's Syndrome
Interventions: TMTDS; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: Female only
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: ESRD, Hyperkalemia, End Stage Renal Disease
Interventions: Patiromer; Drug
Lead sponsor: Dominic Raj; Other
Eligibility: 18 Years to 85 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Gestational Diabetes
Interventions: GGT/Uric Acid; Diagnostic Test
Lead sponsor: Mount Carmel Health System; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Thymoma, Mediastinal Tumor, Gynecologic Disease, Gynecologic Cancer, Pelvic Organ Prolapse, Prostate Disease, Prostate Cancer, Inguinal Hernia, Ventral Hernia, Obesity, Morbid
Interventions: Robotic-assisted Surgery; Device
Lead sponsor: Intuitive Surgical; Industry
Eligibility: 21 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 4
States / cities: Orlando, Florida • Lansing, Michigan • Ridgewood, New Jersey + 1 more

Conditions: Gestational Diabetes Mellitus, Exercise
Interventions: Moderate-to-vigorous intensity exercise; Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions: Paricalcitol, Calcitriol; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 4
States / cities: Chicago, Illinois • Evanston, Illinois • Detroit, Michigan + 1 more

Conditions: Anemia, Iron Deficiency, Heavy Menstrual Bleeding
Interventions: Ferumoxytol, Ferrous Sulfate; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Type 1 Diabetes Mellitus, Diabetic Ketoacidosis
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 3 Years to 18 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Aurora, Colorado

Search by objective public record fields.

Rural Hospital-Level Care at Home for Acutely Ill Adults

NT-ProBNP-based Heart Failure Screening and Prevention Trial in Patients With Type 2 Diabetes: STRONG-DM Study

OneinSeven Gestational Diabetes Genetic and Socioeconomic Risk Study

Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Renal Impairment

Caloric Intake and Ovarian Reserve

NT-proBNP Levels and Obesity in Pregnancy

Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS

Phase IV Study to Evaluate the Efficacy of AMNIOEXCEL in Diabetic Foot Ulcers

Effects of a Non-nutritive Sweetener Reduction Intervention in Pregnancy and Lactation on Maternal and Infant Outcomes

Cholecalciferol Versus Doxercalciferol in the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease

Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients

NAD Augmentation in Diabetes Kidney Disease

TODAY2 Phase 1 Immediate Post-Intervention Observational Follow-up Study

Comparative Effectiveness of Metformin for Type 2 Diabetes With Chronic Kidney Disease

Continuous Delivery of Ranibizumab Via the Port Delivery System for Proliferative Diabetic Retinopathy-related Vitreous Hemorrhage With Pars Plana Vitrectomy and Limited PRP.

A Pragmatic Approach to Lower Diabetes Risk After Gestational Diabetes

Hormone Replacement Therapy to Treat Turner Syndrome

The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia

GGT and Uric Acid to Predict Gestational Diabetes Mellitus

Clinical Investigation of the da Vinci Surgical System

Moderate-to-vigorous Physical Activity for Glycemic Control in Patients With Gestational Diabetes Mellitus

Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT)

IV Iron vs Oral Iron for Treatment of Anemia in Women With Abnormal Uterine Bleeding

Diabetic Kidney Alarm (DKA) Study